These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 32361894)

  • 1. A Preclinical Investigation into the Effects of Aging on Dermal Hyaluronan Properties and Reconstitution Following Recombinant Human Hyaluronidase PH20 Administration.
    Connor RJ; Blouw B; Cowell J; Chen K; Zhao C; Kang DW
    Dermatol Ther (Heidelb); 2020 Jun; 10(3):503-513. PubMed ID: 32361894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of computed tomography to assess subcutaneous drug dispersion with recombinant human hyaluronidase PH20 in a swine model.
    Connor RJ; Taverna DM; Thrall K; LaBarre MJ; Kang DW
    J Pharmacol Toxicol Methods; 2020; 106():106936. PubMed ID: 33191187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ENHANZE
    Locke KW; Maneval DC; LaBarre MJ
    Drug Deliv; 2019 Dec; 26(1):98-106. PubMed ID: 30744432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of recombinant human hyaluronidase PH20 for subcutaneous drug delivery.
    Knowles SP; Printz MA; Kang DW; LaBarre MJ; Tannenbaum RP
    Expert Opin Drug Deliv; 2021 Nov; 18(11):1673-1685. PubMed ID: 34585991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifying a predictive relationship between maximal flow rate and viscosity for subcutaneous administration of macromolecules with recombinant human hyaluronidase PH20 in a miniature pig model.
    Connor RJ; Clift R; Kang DW
    Drug Deliv; 2023 Dec; 30(1):2252999. PubMed ID: 37702020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dispersive effects and focused biodistribution of recombinant human hyaluronidase PH20: A locally acting and transiently active permeation enhancer.
    Kang DW; Bittner B; Sugarman BJ; Zepeda ML; Printz MA
    PLoS One; 2021; 16(7):e0254765. PubMed ID: 34292990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Removal of interstitial hyaluronan with recombinant human hyaluronidase improves the systemic and lymphatic uptake of cetuximab in rats.
    Styles IK; Feeney OM; Nguyen TH; Brundel DHS; Kang DW; Clift R; McIntosh MP; Porter CJH
    J Control Release; 2019 Dec; 315():85-96. PubMed ID: 31655131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Hyaluronidase PH20 Administered Intravenously in Healthy Volunteers.
    Printz MA; Dychter SS; DeNoia EP; Harrigan R; Sugarman BJ; Zepeda M; Souratha J; Kang DW; Maneval DC
    Curr Ther Res Clin Exp; 2020; 93():100604. PubMed ID: 32963641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanistic Modeling of the Effect of Recombinant Human Hyaluronidase (rHuPH20) on Subcutaneous Delivery of Cetuximab in Rats.
    Gao X; Lee J; Deshpande K; Kang DW; Fathallah AM; Kagan L
    Pharm Res; 2022 Aug; 39(8):1867-1880. PubMed ID: 35778631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant human hyaluronidase PH20-mediated dermal spreading activity in mice is not altered by steroids, antihistamines, or salicylic acid.
    Cowell JA; Printz MA; Thompson CB
    Drug Metab Pers Ther; 2020 Dec; ():. PubMed ID: 33780198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk Factors, Hyaluronidase Expression, and Clinical Immunogenicity of Recombinant Human Hyaluronidase PH20, an Enzyme Enabling Subcutaneous Drug Administration.
    Printz MA; Sugarman BJ; Paladini RD; Jorge MC; Wang Y; Kang DW; Maneval DC; LaBarre MJ
    AAPS J; 2022 Oct; 24(6):110. PubMed ID: 36266598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subcutaneous Injection Performance in Yucatan Miniature Pigs with and without Human Hyaluronidase and Auto-injector Tolerability in Humans.
    Shi GH; Connor RJ; Collins DS; Kang DW
    AAPS PharmSciTech; 2021 Jan; 22(1):39. PubMed ID: 33409604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolerability and pharmacokinetic properties of ondansetron administered subcutaneously with recombinant human hyaluronidase in minipigs and healthy volunteers.
    Dychter SS; Harrigan R; Bahn JD; Printz MA; Sugarman BJ; DeNoia E; Haughey DB; Fellows D; Maneval DC
    Clin Ther; 2014 Feb; 36(2):211-24. PubMed ID: 24486335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant human hyaluronidase PH20 (rHuPH20) facilitates subcutaneous infusions of large volumes of immunoglobulin in a swine model.
    Kang DW; Jadin L; Nekoroski T; Drake FH; Zepeda ML
    Drug Deliv Transl Res; 2012 Aug; 2(4):254-64. PubMed ID: 25787031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The INFUSE-Morphine study: use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneously administered morphine in patients with advanced illness.
    Thomas JR; Wallace MS; Yocum RC; Vaughn DE; Haller MF; Flament J
    J Pain Symptom Manage; 2009 Nov; 38(5):663-72. PubMed ID: 19819665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-Vivo Efficacy of Recombinant Human Hyaluronidase (rHuPH20) Injection for Accelerated Healing of Murine Retrocalcaneal Bursitis and Tendinopathy.
    Rezvani SN; Chen J; Li J; Midura R; Cali V; Sandy JD; Plaas A; Wang VM
    J Orthop Res; 2020 Jan; 38(1):59-69. PubMed ID: 31478241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration.
    Rosengren S; Dychter SS; Printz MA; Huang L; Schiff RI; Schwarz HP; McVey JK; Drake FH; Maneval DC; Kennard DA; Frost GI; Sugarman BJ; Muchmore DB
    AAPS J; 2015 Sep; 17(5):1144-56. PubMed ID: 25967925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A recombinant human hyaluronidase sustained release gel for the treatment of post-surgical edema.
    Nekoroski T; Paladini RD; Sauder DN; Frost GI; Keller GA
    Int J Dermatol; 2014 Jun; 53(6):777-85. PubMed ID: 24168080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The INFUSE-Morphine IIB study: use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneous morphine in healthy volunteers.
    Thomas JR; Yocum RC; Haller MF; Flament J
    J Pain Symptom Manage; 2009 Nov; 38(5):673-82. PubMed ID: 19819667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and pharmacokinetics of subcutaneous ceftriaxone administered with or without recombinant human hyaluronidase (rHuPH20) versus intravenous ceftriaxone administration in adult volunteers.
    Harb G; Lebel F; Battikha J; Thackara JW
    Curr Med Res Opin; 2010 Feb; 26(2):279-88. PubMed ID: 19947907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.